



Oxilio Announces Start of its First Clinical Trial with OXL001

Oxford, UK; November 6th, 2022 - Oxilio, a pioneering drug development company repurposing existing drugs to address unmet needs in cancer treatment, today announced that it has commenced first human subject dosing with OXL001. This first study is designed to investigate the pharmacokinetics (PK) and safety of various doses of OXL001 in healthy volunteers.

Oxilio's lead product, OXL001, has been developed utilising a novel bio-enabling platform technology created by our development partner, TRx Biosciences, and Quotient Sciences' integrated drug development, manufacturing, and clinical testing platform Translational Pharmaceuticals®

Dr Simon Yaxley, Director of Oxilio, said: *"Working together with our partners Quotient Sciences and TRx Biosciences we are pleased to have been able to move rapidly into the clinic following recent approval for this study by the UK Medicines and Healthcare products Regulatory Agency (MHRA). This is an important milestone for the business, and we look forward to providing the resulting study data at the earliest opportunity."*

Dr Robin Bannister, CEO of TRx Biosciences, added: *"Our work with Oxilio and the unique development challenges in repurposing OXL001 into oncology have resulted in significant advancement of TRx's underlying technology and we're delighted to now see the progression of OXL001 into the clinic, given its immense potential as a pan-cancer therapy. We will continue to support Oxilio throughout its clinical development activities, which will further validate our targeted oral delivery platform"*

Dr Mark Egerton, CEO of Quotient Sciences, said: *"Quotient Sciences is proud to have helped the Oxilio team achieve this important milestone. Our unique Translational Pharmaceuticals platform allowed us to rapidly progress OXL001 into the clinic and now both Oxilio and TRx Biosciences can make informed decisions based on emerging clinical data to improve the potential of downstream success. We will continue supporting Oxilio with our integrated capabilities to accelerate the development timeline of OXL001, and ultimately get this life-changing therapy to patients faster."*

About Oxilio

Oxilio is a pioneering pharmaceutical drug development company improving cancer treatment through rapid, cost-effective drug development. Our mission is to identify, repurpose, and commercialize existing drugs to address unmet needs in cancer therapy. We find new uses for old drugs, a proven approach that involves less risk, time, and cost to bring a drug to the marketplace. Through repurposing, reformulation, and gold-standard modelling and simulations, we are fast-tracking disruptive drug development at speed and at low cost.

For more information, please visit Oxilio.co.uk

Oxilio Company Contact: info@oxilio.co.uk

About Quotient Sciences

Quotient Sciences is a drug development and manufacturing accelerator providing integrated programs and tailored services across the entire development pathway. Cutting through silos across a range of drug development capabilities, we save precious time and money in getting drugs to patients. Everything we do for our customers is driven by an unswerving belief that ideas need to become solutions, and molecules need to become cures, fast. Because humanity needs solutions, fast.

For more information, please visit quotientsciences.com.

Quotient Sciences Company Contact:

Kimberly Burrell - Executive Director of Global Marketing (509) 910-1551

Kimberly.Burrell@QuotientSciences.com

About TRx Biosciences

TRX's technology enables targeted oral drug delivery to specific organs, cells and tissues in cancer, CNS and respiratory diseases and diseases of the immune system using a clinically and commercially proven approach. Our bio-enabling delivery mechanism addresses bioavailability, solubility and permeability limitations simultaneously, whilst allowing drugs to be highly targeted towards specific cells and tissues to best leverage their pharmacology. Our data demonstrates that TRx technology has the potential to significantly enhance the design and development of existing and future small molecule-based therapies.

For more information, please visit trxbiosciences.com

TRx Biosciences Company Contact: dan.gooding@trxbiosciences.com